Gel'tser B I, Rubashek I A, Semisotova E F, Kramar A V
Ter Arkh. 1996;68(12):22-5.
A clinical trial was made of the efficacy of macrolide antibiotic rovamycin (spiromycin) in 30 patients (mean age 35 +/- 12 years) with moderate extrahospital pneumonia. In group I (12 patients) with affection of at least 2 lung segments rovamycin was intravenously infused for 3 days (3,000,000 IU 2 times a day), then given orally for 5 days (3,000,000 IU 2 times a day every 12 hours). 18 patients of group 2 with 1-2 affected lung segments received rovamycin per os for 5-7 days three times a day (9,000,000 IU a day). Pneumonia etiology was verified in 22 patients. Str. pneumonia, Hemophilus influenzae, Staph, aureus. Str. pyogenes were registered in 10, 3, 2, 2 cases, respectively. Five patients had associations of gram-positive and gram-negative bacteria. Hospital stay lasted 13.4 +/- 0.7 days. At the end of the second week of the treatment pneumonia resolved in 100% of patients. Rovamycin proved low toxic and well tolerated.
对30例（平均年龄35±12岁）中度院外肺炎患者进行了大环内酯类抗生素罗伐霉素（螺旋霉素）疗效的临床试验。在第I组（12例患者）中，至少2个肺段受累，罗伐霉素静脉输注3天（300万IU，每日2次），然后口服5天（300万IU，每12小时2次）。第2组18例1-2个肺段受累的患者口服罗伐霉素5-7天，每日3次（每日900万IU）。对22例患者的肺炎病因进行了验证。分别在10例、3例、2例、2例中发现肺炎链球菌、流感嗜血杆菌、金黄色葡萄球菌、化脓性链球菌。5例患者有革兰氏阳性菌和革兰氏阴性菌合并感染。住院时间为13.4±0.7天。治疗第二周结束时，100%的患者肺炎得到缓解。罗伐霉素毒性低，耐受性好。
